Evidence map›Paper›PMID 42387447›Full record

ArticleBMC cancer2026

Analysis of factors influencing SARS-CoV-2 infection and outcomes in patients with chronic lymphocytic leukemia during the burst of COVID-19 epidemic.

J Wang, S Wang, F Xu, H Hu, Y P Liu, X G Liang, G P Feng, B Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

J Wang *Department of Hematology, School of Medicine, Mianyang Central Hospital, University of Electronic Science and Technology of China, Mianyang, China.
S Wang *Department of Hematology, School of Medicine, Mianyang Central Hospital, University of Electronic Science and Technology of China, Mianyang, China.
F XuDepartment of Hematology, School of Medicine, Mianyang Central Hospital, University of Electronic Science and Technology of China, Mianyang, China. 147377807@qq.com.
H HuDepartment of Hematology, School of Medicine, Mianyang Central Hospital, University of Electronic Science and Technology of China, Mianyang, China.
Y P LiuDepartment of Hematology, School of Medicine, Mianyang Central Hospital, University of Electronic Science and Technology of China, Mianyang, China.
X G LiangDepartment of Hematology, School of Medicine, Mianyang Central Hospital, University of Electronic Science and Technology of China, Mianyang, China.
G P FengDepartment of Hematology, School of Medicine, Mianyang Central Hospital, University of Electronic Science and Technology of China, Mianyang, China.
B ChenDepartment of Hematology, School of Medicine, Mianyang Central Hospital, University of Electronic Science and Technology of China, Mianyang, China.

Funding

The Health Humanities Research Center of China JKRWZ23-04The hospital-level research project from Mianyang Central Hospital 2023YJ013
6 · The paper itself

Abstract

backgroundCLL patients have immune deficiencies and are at high risk of SARS-CoV-2 infection. Limited research exists on risk factors and survival outcomes of SARS-CoV-2 infection in Asian CLL patients during the COVID-19 pandemic. Therefore, this study aims to explore the relationship between SARS-CoV-2 infection and survival in this population.

methodsA retrospective analysis was conducted on 119 CLL patients treated at a large tertiary comprehensive hospital in western China from January 2020 to May 2023, coinciding with a surge in the epidemic in the city.

results(1) During the epidemic, the treatment group had a higher proportion of males, second-line and initial treatment, 11q- chromosome, LDH level, and lower erythrocyte count (P < 0.05). Patients in this group had longer median duration of malaise, more headaches and coughs, longer cough and sputum duration, higher rates of hyposmia, and more patients received antiviral treatment for COVID-19 and suffered weight loss. The treatment group had more CLL patients affected by SARS-CoV-2, and more patients developed secondary COVID-19 infection, and had lower RBC count and hemoglobin levels (P < 0.05). (2) Compared to the non-BTKi treatment group, more patients in BTKi treatment received treatment lasting ≥ 1 month, more had abnormal karyotyping, high-risk cytogenetics, less recent cytotoxic drug and rituximab exposure, lower lymphocyte count, elevated creatinine level, and lower glomerular filtration rate (P < 0.05). (3) Firth's penalised-likelihood logistic regression revealed that male sex increased hospitalization risk, while normal karyotyping decreased this risk. Male sex and recent rituximab exposure (within 6 months) were SARS-CoV-2 infection risk factors. Both frontline and second-or-more line therapies were associated with higher SARS-CoV-2 mortality risk compared to untreated patients (all P < 0.05).

conclusionMale sex and recent exposure to rituximab within the past six months are risk factors for SARS-CoV-2 infection in CLL patients. Both frontline and second-or-more line therapies are risk factors for mortality (compared to untreated patients). Treatment with BTK inhibitors does not increase the risk of SARS-CoV-2 infection or mortality.

Indexed as

COVID-19Leukemia, Lymphocytic, Chronic, B-CellAgedAged, 80 and overAntiviral AgentsChinaFemaleHumansMaleMiddle AgedPandemicsRetrospective StudiesRisk FactorsRituximabSARS-CoV-2Antiviral AgentsRituximabChronic lymphocytic leukemiaCOVID-19InfectionSurvival outcomeTreatment

Identifiers

PMID42387447
PMCPMC13595660

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.